Alex Brill recently joined Garrett Ballengee, founding executive director of the Cardinal Institute for West Virginia Policy, on their podcast “Forgotten America.” In this fascinating interview, Brill discusses the economic impacts of the opioid crisis in America, noting that the epidemic is no longer just an Appalachian problem.
Four years ago, many commentators lamented that Hillary Clinton fell short of winning the Electoral College by less than 80,000 votes. “You Could Fit All the Voters Who Cost Clinton the Election in a Mid-Sized Football Stadium,” read a headline in Vanity Fair. Now, it is not just Hillary Clinton that lost by a hair.
“‘The nursing home COVID crisis in New York and New Jersey and Connecticut from the beginning of the pandemic, things are different and way better there. But as the pandemic is spreading throughout the country, we’re going to see it pop up in other nursing homes’ Brill said.”
From both a public health and economic perspective, the coronavirus pandemic has wreaked havoc on our country. More than 210,000 people have died, more than 435,000 individuals have been hospitalized, and more than 10 million jobs have been lost nationally. The US economy was 10 percent smaller in June than it was last December and is not projected to fully recover until some point in 2021 at the earliest.
“‘I think it creates confusion for the negotiators. Republicans on the Hill are looking for a signal from the president. They are looking for leadership on this, and he’s oscillating,’ Brill said.”
“The report finds that extending patents on just those five drugs [Prilosec, TriCor, Suboxone, Doryx, and Namenda] will result in a cost to the U.S. health care system of $4.7 billion annually—money that in theory could have been saved if the drugs had been available in a generic form.”
We recently had the honor of testifying before the House Ways and Means Committee on the effects of inaction on coronavirus fiscal legislation. One of us was invited by the Republicans and the other by the Democrats. The basis of the hearing was the Heroes Act, a $3 trillion bill that passed the House in the spring on a party line vote with about $1 trillion in tax cuts and $2 trillion in new spending.
Brand-name Drugmaker Tactic ‘Product Hopping’ Costs US Healthcare System $4.7 Billion Annually, Study Says
“An anti-competitive tactic used by brand-name drugmakers called product hopping costs the U.S. healthcare system at least $4.7 billion annually, according to a study from Matrix Global Advisors.”
New Report Shows Brand Drug Product Hopping Costs Billions for Patients and Healthcare System Each Year
Report details five instances of product hopping that collectively cost $4.7 billion annually.
“But Alex Brill of the right-leaning American Enterprise Institute said Congress shouldn’t approve more costly economic recovery payments because they aren’t well targeted toward households directly impacted by the pandemic.”
My testimony begins with an overview of the economic impact of the pandemic and our current economic situation.
“That’s an impossible bar to clear, writes Alex Brill, an economist with Matrix Global Advisors and a fellow at the American Enterprise Institute, in a new report sponsored by the PBM lobby Pharmaceutical Care Management Association.”
Matrix Global Advisors (MGA) today released a new report, “Negative Economic Impact of Restricting Drug Rebates in Medicare Part D,” by MGA founder and CEO Alex Brill. The report looks at a July 2020 Executive Order on prescription drug rebates that invokes a proposed regulatory change President Trump withdrew a year earlier.
“The Chamber of Commerce cites a new report from economic policy consulting firm Matrix Global Advisors on the negative economic effects of expanded Medicare and a public option.”
Matrix Global Advisors (MGA) today released a new report, “The Negative Economic Effects of Medicare Buy-In and Public Option Proposals,” by MGA founder and CEO Alex Brill.
Have a Question?
Get In Touch
Get Our latest news
1350 Connecticut Avenue NW
Washington, DC 20036